Market revenue in 2023 | USD 8,267.5 million |
Market revenue in 2030 | USD 16,113.5 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Infusion Pumps |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 23.22% in 2023. Horizon Databook has segmented the Japan drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
Japan’s rapidly aging population, characterized by a substantial elderly demographic facing various chronic health conditions, has increased the demand for efficient and patient-friendly drug delivery methods. This demographic shift has prompted the adoption of drug-device combination products as a viable solution, supported by Japan’s healthcare system, which prioritizes technological advancements and patient-centric care.
The noninvasive nature of drug-device combination products and their ability to enhance patient adherence to treatment regimens further contribute to their acceptance & utilization in Japan. Furthermore, the growing awareness about the preventive use of medical devices to mitigate respiratory failure complications, growing advancements in healthcare infrastructure, and increasing healthcare expenditure are expected to propel market growth over the forecast period.
In addition, the rising geriatric population is considered a key driver of the drug device combination products market. According to the World Economic Forum, over 1 in 10 people in the country were aged 80 and above in 2023. Hence, the large geriatric population is boosting the prevalence of chronic diseases, including COPD and heart failure, due to high comorbidities.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into Japan drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account